Skip to search boxSkip to navigationSkip to main content

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

  • Gaël G. McGill
    ,
  • Martin Horstmann
    ,
  • Hans R. Widlund
    ,
  • Jinyan Du
    ,
  • Gabriela Motyckova
    ,
  • Emi K. Nishimura
*Corresponding author for this work
  • Dana-Farber Cancer Institute
    ,
  • Whitehead Institute for Biomedical Research
    ,
  • Howard Hughes Medical Institute
    ,
  • ,
  • Western General Hospital
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Kit/SCF signaling and Mitf-dependent transcription are both essential for melanocyte development and pigmentation. To identify Mitf-dependent Kit transcriptional targets in primary melanocytes, microarray studies were undertaken. Among identified targets was BCL2, whose germline deletion produces melanocyte loss and which exhibited phenotypic synergy with Mitf in mice. BCL2's regulation by Mitf was verified in melanocytes and melanoma cells and by chromatin immunoprecipitation of the BCL2 promoter. Mitf also regulates BCL2 in osteoclasts, and both Mitfmi/mi and Bcl2-/- mice exhibit severe osteopetrosis. Disruption of Mitf in melanocytes or melanoma triggered profound apoptosis susceptible to rescue by BCL2 overexpression. Clinically, primary human melanoma expression microarrays revealed tight nearest neighbor linkage for MITF and BCL2. This linkage helps explain the vital roles of both Mitf and Bcl2 in the melanocyte lineage and the well-known treatment resistance of melanoma.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 707-718 (12 pages)

Journal (Volume, Issue Number)

Cell (Volume 109, Issue 6)

Publication milestones

  • Published - 06/14/2002

Publication status

Published - 06/14/2002

ISSN

0092-8674

Publication IDs

  • Scopus: 18444418797
  • PubMed: 12086670
  • ORCID: /0000-0001-5702-3439/work/67683805

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
7.90
SciVal
Author count
15
SciVal
citations
563
SciVal
Paper percentile
99
SciVal
Top percentile
1
Fractional count
1
Fractional count
0.07
Fractional count
14
Fractional count
0.93
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
315
Citation count
658
Mentions
4

Funding Details

We thank Wade Huber for adenovirus production and technical assistance; Cliff Takemoto with help in early aspects of this work; David Rowitch and members of the Rowitch lab for technical assistance with microscopy; Ruth Halaban for melanocytes and melanoma cells; and Scott Granter, Robert Martinez, Roydon Price, Junqing Cui, Min Wu, and other members of the Fisher lab for helpful contributions. We also thank Dr. Michael Greenberg, Dr. Christopher T. Walsh, and Dr. Junying Yuan for helpful comments. G.G.M. is supported by the Howard Hughes Medical Institute Predoctoral Fellowship and a Sandoz Fellowship. M.H. was supported by the Mildred-Scheel-Foundation of Deutsche Krebshilfe. H.R.W. is a Swedish Wenner-Gren postdoctoral fellow, S.R. is supported by a Harvard Medical School/National Institutes of Health Training Grant in Molecular Hematology, and S.A.J. was a European Molecular Biology Organization Fellow. This work was supported in part by grants from NIH (CA50239) to S.J.K.; Bristol-Myers Squibb, Millennium Pharmaceuticals, and Affymetrix, Inc. to T.R.G., and from NIH (AR43369 and AR45662) to D.E.F. D.E.F. is Jan and Charles Niremberg Fellow at the Dana-Farber Cancer Institute. This paper is dedicated to the memory of Mary Kaye Waldron (1972–1995).
FundersFunding numbers
Affymetrix, Inc.
AR43369, AR45662
Harvard Medical School/National Institutes of Health
-
NIH
-
HHMI
-
NCI
R37CA050239
DFCI
-
Deutsche Krebshilfe
-